

6.2

6.2.1 Parent company financial statements of bioMérieux SA for the financial years ended December 31, 2018 and 2019

Balance sheet

<i>In millions of euros</i>	Notes	Net Dec. 31, 2019	Net Dec. 31, 2018
Fixed assets			
• Intangible assets	3.1	182.4	191.7
• Property, plant and equipment	3.2	270.8	247.8
• Investments and related receivables	3.3	748.3	731.4
• Other non-current financial assets	3.3	11.1	10.3
TOTAL		1,212.7	1,181.2
Current assets			
• Inventories and work-in progress	4	149.5	161.5
• Trade receivables	5	387.0	360.4
• Other operating receivables	5	34.3	32.8
• Non-operating receivables		20.1	31.1
• Cash and cash pooling	6	219.1	225.8
TOTAL		810.0	811.6
Deferred charges spread over several years		0.4	0.6
Bond redemption premiums		0.3	0.6
Unrealised foreign exchange losses	7	2.4	4.3
TOTAL ASSETS		2,025.7	1,998.3

<i>In millions of euros</i>	Notes	Dec. 31, 2019	Dec. 31, 2018
Shareholders' equity			
• Share capital		12.0	12.0
• Additional paid-in capital		63.5	63.5
• Reserves		877.7	843.9
• Statutory provisions and grants		60.4	60.0
• Net income for the year		119.6	75.1
TOTAL	8	1,133.2	1,054.5
Impairment	9	52.1	63.1
Liabilities			
• Borrowings and debt	10	493.2	548.9
• Trade payables	11	168.7	163.9
• Other operating payables	11	142.6	144.4
• Non-operating payables		35.6	22.8
TOTAL		840.1	880.0
Unrealised foreign exchange gains	7	0.2	0.7
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		2,025.7	1,998.3

Consolidated income statement

<i>In millions of euros</i>	2019	2018
Sales of goods and finished products	1,046.2	1,008.1
Other income	212.0	180.6
SALES	1,258.2	1,188.8
Production included in inventories (work-in-progress and finished products)	(3.7)	(2.8)
Capitalised production	11.2	7.8
TOTAL PRODUCTION	1,265.7	1,193.8
Purchases	(441.6)	(445.9)
Change in raw material and instrument inventories	(7.8)	16.5
External charges	(322.0)	(275.5)
ADDED VALUE	494.3	488.9
Taxes other than income tax	(20.6)	(21.6)
Payroll and benefits	(309.7)	(313.5)
GROSS OPERATING INCOME	164.0	153.9
Depreciation, amortisation and provisions	(62.5)	(50.7)
Other operating income (expense)	(44.0)	(44.9)
OPERATING INCOME	57.5	58.2
Net financial expense	(1.7)	(4.2)
Net investment income	38.5	16.8
NET INCOME BEFORE NON-RECURRING ITEMS AND TAX	94.2	70.8
Non-recurring income	26.4	3.7
Income tax	(1.1)	0.6
NET INCOME	119.6	75.1
BASIC EARNINGS PER SHARE	1.01	0.64

Basic earnings per share is calculated by dividing net income by the weighted average number of shares outstanding during the period (excluding shares intended for allocation under free share grants and treasury shares held for market-making purposes).

Diluted (net) earnings per share are calculated from the number of shares defined in the basic earnings increased by the weighted average number of potential shares to be issued and which would have a dilutive effect on net income. They stood at 1.01 for 2019 and 0.63 for 2018.

6.2.2

Note 1	General accounting principles	243	Note 11	Trade and operating payables	260
Note 2	Significant events of the fiscal year	243	Note 12	Accrued expenses and income	261
Note 3	Fixed assets	244	Note 13	Sales	261
Note 4	Inventories	252	Note 14	Research & development expenses	262
Note 5	Trade and operating receivables	252	Note 15	Personnel costs and employee benefits	262
Note 6	Cash at bank and in hand	253	Note 16	Net financial expenses	263
Note 7	Translation adjustments	254	Note 17	Non-recurring income	264
Note 8	Equity and share grant plans	255	Note 18	Corporate income tax	264
Note 9	Provisions for contingencies and losses	257	Note 19	Hedging instruments	266
Note 10	Net debt	258	Note 20	Off-balance sheet commitments	268
			Note 21	Related parties	269

Note 1 General accounting principles

The financial statements have been prepared in accordance with regulation No. 2015-06 and No. 2016-07 of the French accounting standards authority (*Autorité des normes comptables* – ANC).

The Company prepares consolidated financial statements which include the annual financial statements of its subsidiaries based on the full consolidation method whenever bioMérieux has effective control

over those subsidiaries, or based on the equity method when the Company exercises significant influence over the entities concerned.

The Company's financial statements are fully consolidated in the financial statements of Compagnie Mérieux Alliance (17 rue Bourgelat, 69002-Lyon, France).

Note 2 Significant events of the fiscal year

2.1 Change in the securities portfolio

In 2019, bioMérieux SA subscribed to the capital of several subsidiaries for a total of €74.5 million, including:

- the capital increase of bioMérieux China for €64.2 million (US\$72 million);
- part of the capital in bioMérieux Suzhou Biotech Co. Ltd. paid up for €7 million (54.5 million Chinese yuan);
- the capital increase of bioMérieux Argentina for €2.9 million (142.6 million Argentine pesos).

The bioMérieux Hong Kong Investment subsidiary carried out a capital reduction by reducing the par value of its shares, thus reducing the value of the securities held by bioMérieux SA by €6 million.

Lastly, all of the Quanterix securities, historically valued at €17.9 million, were sold for €48.4 million in 2019, thus generating a gain of €30.5 million recorded in non-recurring income.

2.2 Subsidiaries financing

In 2019, bioMérieux SA supported the financing of the growth and creation of its subsidiaries by granting loans to bioMérieux South Africa and bioMérieux Egypt for €6.3 million and €1 million, respectively.

The loan granted to bioMérieux Inc. in 2014 to finance the acquisition of BioFire was repaid for €49.2 million during the fiscal year.

2.3 Employee share ownership plan

In 2019, the Company launched an employee share ownership plan open to all Group employees. Employees benefited from a subscription price of €52.22 per share, discounted by 30% compared to the reference price (€74.60), and a matching contribution of 100% of the amount of subscriptions up to €1,000 per employee. Employees subscribed to 320,841 shares (of which 173,045 shares for French employees), and the Company delivered 402,168 shares (of which 214,229 shares for French employees), taking into account the discount and matching contribution. The cost of the plan recognised in operating income/expenses was €7.4 million. The cost of the plan for the employees of other Group companies was fully rebilled to the subsidiaries and did not have an impact on operating income.

2.4 Significant subsequent events

There was no significant subsequent event.

Note 3 Fixed assets

3.1 Intangible assets

3.1.1

In accordance with regulation ANC No. 2015-06, technical merger losses were assigned to specific fixed asset accounts in January 2016 relating to acquired goodwill such as intangible business assets, technology and customer relations.

Historical goodwill and assets originating from the assignment of technical elements merger losses do not constitute stand-alone individual items that can generate their own cash flow. They are intrinsically attached to plants, to the R&D effort that supports the acquired range, to technology and the sales forces that contribute to distributing the product ranges across the Group's entire distribution channels.

Acquired goodwill is therefore grouped together with the other assets of the technological range to which they are linked in order to constitute a homogeneous and stand-alone range. In practice, tests are performed to group together assets that serve the same client typology (industrial microbiology laboratories) or health issue (pathology/detection of disease-causing organisms: microbiology, molecular biology or immunoassays). An impairment test is carried out systematically from asset groups close to the groups identified at Group level (CGU) when their

analysis reveals their fungibility (monitoring and pooled management of acquired goodwill by technological range and customer typology).

At each year-end, the net value of the asset groups thus identified is compared with the current value of assets determined from discounted net cash generated by these assets (including acquired goodwill). An impairment is recorded if a loss of value is observed.

Intangible assets also include software applications acquired or developed in-house, amortised over periods of three to ten years based on their estimated useful lives, and patents and licences amortised over the contractual or statutory term of use. In practice, a period of five years is usually applied. These assets are measured at cost (purchase price and incidental costs) or at their production cost.

Lastly, intangible assets acquired in exchange for the payment of indexed royalties are measured at the time of acquisition on the basis of estimated future royalties to be paid over the term of the contract. These estimates are subsequently adjusted based on royalties effectively paid.

3.1.2

Breakdown <i>In millions of euros</i>	Gross value	Accumulated depreciation & impairment losses	Carrying amount 12/31/19	Carrying amount 12/31/18
R&D expenses	17.2	16.7	0.5	1.1
Software	89.7	71.2	18.5	18.6
Goodwill and intangible business assets	142.4 ^(a)	3.9	138.5	142.4
Assets under construction	3.2		3.2	13.1
Other	57.5 ^(b)	35.8 ^(c)	21.7	16.5
TOTAL	309.9	127.6	182.4	191.7

(a) Including acquired goodwill linked to the assignment of merger losses: €130.4 million.

(b) Including technologies and customer relationships following the assignment of merger losses: €35.7 million and distribution rights for Suzhou Hybiome Biomedical Engineering Co.Ltd.: €7.5 million.

(c) Including amortisation of the technologies and customer relations linked to the assignment of merger losses: €21.8 million.

Change <i>In millions of euros</i>	Gross value	Accumulated depreciation and impairment	Net Value
DECEMBER 31, 2018	309.2	117.5	191.7
Acquisitions/Increases	7.0	14.4	(7.5)
Disposals/Decreases	(6.1)	(4.3)	(1.9)
DECEMBER 31, 2019	310.0	127.6	182.4

The increase in the gross value of intangible assets over the year primarily corresponds to the acquisition of software and the development costs of IT solutions for €6.7 million (mainly external costs).

The decrease in the gross value of intangible assets over the year primarily corresponds to scrapped unused licences for €3.8 million and disposals of software and development costs for IT solutions for €2.3 million.

The increase in amortisation and impairment during the fiscal year results from the amortisation of software for €7.6 million, impairment of goodwill for €3.9 million, amortisation of merger losses for €2.3 million, and amortisation or impairment of research & development expenses previously capitalised by AES Chemunex for €0.5 million. These research & development expenses are being amortised over a period of five years.

Technical merger losses are allocated as follows:

<i>In millions of euros</i>	Gross value	Accumulated depreciation	Carrying amount
AES Chemunex			
Goodwill	111.0		111.0
Technology	12.5	7.9	4.6
Customer relationships	5.4	2.6	2.8
TOTAL	128.9	10.5	118.4
Argène			
Goodwill	19.4		19.4
Technology	12.8	7.6	5.2
TOTAL	32.2	7.6	24.6
CEERAM			
Technology	2.4	1.1	1.3
TOTAL	2.4	1.1	1.3
Advencis			
Technology	2.6	2.6	
TOTAL	2.6	2.6	
TOTAL	166.1	21.8	144.3

3.2 Property, plant and equipment

3.2.1

Property, plant and equipment are shown on the balance sheet at purchase or production cost.

In accordance with rules concerning the recognition of assets in effect since January 1, 2005, components are separately recognised and depreciated whenever their cost represents a significant portion of the total cost of the asset to which they relate and their useful life is not the same as that of the main asset.

The only property, plant and equipment assets to which this method is applied are buildings.

For buildings, the depreciation periods are adapted to each group of components:

Depreciation period	Accounting	Tax
Shell	30-40 years	Straight line basis 30 years
Finishing work, fixtures and fittings	10-20 years	Straight line basis 15 years

The depreciation is calculated using the straight-line method over the estimated useful lives of the various asset categories. The main durations for useful lives are:

Depreciation period	Accounting	Tax
Machinery and equipment	3-10 years	Degrressive 5-10 years
Instruments*	3-10 years	Degrressive 3-5 years

* Instruments either installed at third-party sites or used in-house.

Impairment tests are carried out for property, plant and equipment whenever events or market developments indicate that an asset may have declined in value. If the carrying amount exceeds the recoverable amount, an impairment loss is recognised to reduce the assets to their realisable value.

Most capitalised instruments are installed at customers' sites.

3.2.2

Breakdown <i>In millions of euros</i>	Gross value	Accumulated depreciation & impairment losses	Carrying amount 12/31/19	Carrying amount 12/31/18
Land and land improvements	17.8	1.0	16.8	17.9
Buildings	275.9	165.5	110.4	98.8
Machinery and equipment	216.1	160.2	55.9	58.1
Capitalised instruments	53.0	31.2	21.8	16.3
Other assets	50.6	37.4	13.2	11.1
Fixed assets in progress	52.7		52.7	45.6
TOTAL	666.1	395.3	270.8	247.8

Change <i>In millions of euros</i>	Gross value	Accumulated depreciation and impairment	Net Value
DECEMBER 31, 2018	625.5	377.7	247.8
Acquisitions/Increases	59.3	36.1	23.2
Disposals/Decreases	(18.7)	(18.5)	(0.2)
DECEMBER 31, 2019	666.1	395.3	270.8

The main investments for the fiscal year concern the construction, equipment and fixtures and fittings for the Campus of Craonne for €11 million, and for the Campus of Marcy for €6 million.

3.3 Financial assets

3.3.1

Non-current financial assets are recognised at their purchase price. An impairment loss is recognised against equity investments whenever their value in use falls below their acquisition cost. Value in use is initially estimated taking into account the net carrying amount of the subsidiary's assets at the reporting date. This may be adjusted to reflect the value of any unrecognised identifiable assets (particularly real estate or technologies). Depending on the economic and financial situation of the subsidiary, value in use may also be estimated taking account of sales, borrowings and any associated technological assets and real estate. Given the specific nature of certain investments, in some cases value in use may be measured by estimating the enterprise value based on discounted future cash flows or on observable market financial inputs.

Non-controlling interests held in unlisted companies are measured based on various criteria including the economic outlook, the net equity of the investment or the valuation used based on recent investments in these shares.

Other investments are written down whenever their market value falls below cost. The market value of listed securities corresponds to the average trading price during the last month of the year.

Other non-current financial assets include treasury shares purchased under a liquidity agreement entered into with an investment firm for the specific purpose of maintaining an orderly market in the Company's shares. Own shares held are measured at their average trading price during the last month of the year.

3.3.2

Breakdown <i>In millions of euros</i>	Gross value	Impairment losses	Carrying amount 12/31/19	Carrying amount 12/31/18
Investments	779.4	98.1	681.3	621.0
Other financial assets	20.6	11.5	9.1	8.3
Related receivables	67.0		67.0	110.4
Other	2.0		2.0	2.0
TOTAL	869.0	109.6	759.4	741.7

Change <i>In millions of euros</i>	Gross value	Accumulated depreciation and impairment	Net Value
DECEMBER 31, 2018	847.5	105.8	741.7
Acquisitions/Increases	102.1	4.7	97.3
Disposals/Decreases	(80.5)	(0.9)	(79.6)
DECEMBER 31, 2019	869.0	109.6	759.4



During the 2019 fiscal year, bioMérieux SA subscribed to the capital increases of several subsidiaries: bioMérieux China for €64.2 million (US\$72 million), bioMérieux Argentina for €2.9 million (142.6 million Argentine pesos), and bioMérieux Côte d'Ivoire for €0.2 million (CFA francs 130 million).

In April 2019, the Company subscribed to the unpaid capital of bioMérieux Suzhou Biotech Co. Ltd. for €20 million (150.1 million Chinese yuan). Capital was paid up during the fiscal year for €7 million. At December 31, 2019, the unpaid capital amounted to €12.7 million, and exchange gains were generated for €0.3 million.

The bioMérieux Philippines subsidiary was created during the fiscal year for subscribed capital of €0.2 million.

bioMérieux SA granted a loan of €6.3 million (100 million South African rands) to bioMérieux South Africa and two loans of €1 million to bioMérieux Egypt (€18.1 million in Egyptian pounds).

The decreases in securities and related receivables during the 2019 fiscal year are mainly due to the repayment of the loan granted to the subsidiary bioMérieux Inc. for €49.2 million (US\$67.1 million). At end December 2019, the balance of this loan stood at €48.2 million (US\$67.1 million).

The HK Investment subsidiary carried out a capital reduction by reducing the par value of its shares, thus reducing the value of the securities held by bioMérieux SA by €6 million (HK\$68.1 million).

In December 2019, ABG Stella was absorbed by bioMérieux Inc. without an impact on the share valuation.

bioMérieux Germany repaid the balance of its loan of €1.6 million.

The Company purchased bonds convertible into shares for €0.7 million (US\$0.8 million), took part in the subscription to the Qvella fund for €0.3 million, and subscribed to the capital increase in Lumed Inc. for €0.3 million (Can\$0.5 million).

The Company sold all of the Quanterix shares (see Note 2.1).

The increase in the impairment of non-current financial assets corresponds primarily to impairments recognised on the securities of bioMérieux distribution subsidiaries.

3.3.3

See table below.

	Share capital	Equity other than share capital	Share of holding	Value of the securities held before impairment losses	Value of the securities held after impairment losses	Loans and receivables granted by the Company and not Repaid	Sales total of the last fiscal year	Net profit or net loss of last fiscal year	Dividends received by Company in progress of the fiscal year	Notes
	<i>Currencies in millions</i>	<i>Currencies in millions</i>	<i>In %</i>	<i>In millions of euros</i>	<i>In millions of euros</i>	<i>In millions of euros</i>	<i>Currencies in millions</i>	<i>Currencies in millions</i>	<i>In millions of euros</i>	
A - Subsidiaries (up to 50% owned by bioMérieux)										
AB bioMérieux	SEK	0.2	84.9	100.0%	74.2	8.1	0.0	20.5	3.0	01/01/2019-12/31/19
bioMérieux West Africa	CFA	180.0	289.8	100.0%	0.3	0.3	0.0	119.5	0.0	01/01/2019-12/31/19
bioMérieux Germany	EUR	3.5	18.0	100.0%	3.8	3.8	14.0	1.2	0.0	01/01/2019-12/31/19
bioMérieux Algeria	DZD	58.0	57.8	100.0%	0.6	0.6	0.0	26.2	22.4	01/01/2019-12/31/19
bioMérieux Argentina	ARS	15.4	312.7	99.1%	8.3	4.8	0.0	814.7	108.2	01/01/2019-12/31/19
bioMérieux Asia Pacific PTE Ltd.	SGD	0.0	0.0	100.0%	0.0	0.0	0.0	0.0	0.0	Subsidiary created in 2019
bioMérieux Austria	EUR	0.1	1.5	100.0%	0.1	0.1	0.0	17.5	0.9	01/01/2019-12/31/19
bioMérieux Colombia	COP	0.5	25.4	100.0%	2.2	2.2	0.0	78.3	3.9	01/01/2019-12/31/19
bioMérieux Brazil	BRL	136.8	(91.8)	100.0%	49.7	23.5	0.0	164.1	(3.4)	01/01/2019-12/31/19
bioMérieux Belgium	EUR	0.3	2.5	100.0%	0.3	0.3	0.0	29.4	1.2	01/01/2019-12/31/19
bioMérieux Bénélux BV	EUR	0.0	8.7	100.0%	0.1	0.1	0.0	111.1	1.3	01/01/2019-12/31/19
bioMérieux Chile	CLP	1,686.6	5,252.0	100.0%	3.1	3.1	0.0	18,722.4	600.0	01/01/2019-12/31/19
bioMérieux China	HKD	971.6	156.9	100.0%	112.4	112.4	2.8	255.8	13.8	01/01/2019-12/31/19
bioMérieux Korea	KRW	1,000.0	10,731.3	100.0%	0.7	0.7	0.0	52,862.6	661.4	01/01/2019-12/31/19
bioMérieux Denmark	DKK	0.5	7.9	100.0%	0.5	0.5	0.0	65.0	2.6	01/01/2019-12/31/19
bioMérieux Spain	EUR	0.2	34.0	100.0%	0.6	0.6	2.1	89.1	3.4	01/01/2019-12/31/19

		Share capital	Equity other than share capital	Share of holding	Value of the securities held before impairment losses	Value of the securities held after impairment losses	Loans and receivables granted by the Company and not Repaid	Sales total of the last fiscal year	Net profit or net loss of last fiscal year	Dividends received by Company in progress of the fiscal year	Notes
	Currencies in millions	Currencies in millions	In %	In millions of euros	In millions of euros	In millions of euros	Currencies in millions	Currencies in millions	In millions of euros		
bioMérieux Egypt	EGP	0.2	0.7	100.0%	0.0	0.0	1.0	33.9	0.7	0.0	Subsidiary created in 2019
bioMérieux Finland	EUR	0.0	0.6	100.0%	0.1	0.1	0.0	7.6	0.3	0.3	01/01/2019-12/31/19
bioMérieux Greece	EUR	2.0	3.9	100.0%	4.1	4.1	0.0	15.0	0.9	1.5	01/01/2019-12/31/19
bioMérieux Hungary	HUF	3.0	234.6	100.0%	0.0	0.0	0.3	1,709.3	79.5	0.5	01/01/2019-12/31/19
bioMérieux HK Investment LTD	HKD	0.7	2.7	100.0%	0.1	0.1	0.0	0.0	0.9	1.1	01/01/2019-12/31/19
bioMérieux India	INR	66.0	1,377.0	99.9%	2.9	2.9	0.0	5,341.3	74.0	0.0	01/01/2019-12/31/19
bioMérieux Inc.	USD	0.0	1,214.6	100.0%	397.5	397.5	49.8	1,023.5	161.3	0.0	01/01/2019-12/31/19
bioMérieux Italy	EUR	9.0	26.0	100.0%	12.8	12.8	0.0	130.8	8.1	15.0	01/01/2019-12/31/19
bioMérieux Japan	JPY	0.5	0.6	100.0%	15.4	15.4	0.0	6.3	0.1	0.0	01/01/2019-12/31/19
bioMérieux Kenya	KES	18.3	9.4	100.0%	0.2	0.2	0.0	0.0	8.6	0.0	01/01/2019-12/31/19
bioMérieux Malaysia	MYR	0.1	0.2	100.0%	0.0	0.0	0.1	0.0	0.0	0.0	01/01/2019-12/31/19
bioMérieux Middle East	AED	0.1	1.5	100.0%	0.0	0.0	0.7	0.0	0.4	0.0	01/01/2019-12/31/19
bioMérieux Norway	NOK	2.8	3.7	100.0%	0.3	0.3	0.0	46.7	1.9	0.2	01/01/2019-12/31/19
bioMérieux Philippines	PHP	10.4	0.0	100.0%	0.2	0.2	0.0	0.0	0.0	0.0	Subsidiary created in 2019
bioMérieux Poland	PLN	0.4	24.8	100.0%	1.5	1.5	0.0	104.4	2.8	1.0	01/01/2019-12/31/19
bioMérieux Portugal	EUR	1.6	7.4	100.0%	2.0	2.0	0.0	17.3	1.1	0.0	01/01/2019-12/31/19
bioMérieux Czech Republic	CZK	0.2	13.7	100.0%	0.0	0.0	1.2	886.0	6.6	0.3	01/01/2019-12/31/19
bioMérieux Russia	RUB	55.7	258.0	100.0%	1.3	1.3	0.0	1,435.2	112.8	0.3	01/01/2019-12/31/19
bioMérieux South Africa	ZAR	50.0	72.7	100.0%	5.4	5.4	6.4	380.5	2.9	0.0	01/01/2019-12/31/19
bioMérieux Sweden	SEK	0.5	7.7	100.0%	0.2	0.2	0.0	217.6	3.5	0.2	01/01/2019-12/31/19
bioMérieux Switzerland	CHF	0.4	4.4	100.0%	0.6	0.6	0.0	36.8	2.7	1.5	01/01/2019-12/31/19
bioMérieux Suzhou Biotech Co. Ltd.	CNY	54.5	(5.0)	100.0%	7.0	7.0	0.0	0.0	(5.0)	0.0	Subsidiary created in 2019
bioMérieux Thailand	THB	35.0	50.3	100.0%	0.9	0.9	0.0	547.1	0.0	0.1	01/01/2019-12/31/19
bioMérieux Turkey	TRY	3.3	75.1	100.0%	2.7	2.7	0.0	131.1	10.4	0.0	01/01/2019-12/31/19
bioMérieux UK	GBP	0.0	9.4	100.0%	1.2	1.2	3.6	57.9	4.6	8.1	01/01/2019-12/31/19
bioMérieux Vietnam	VND	6.3	1.2	100.0%	0.2	0.2	0.0	0.0	1.1	0.1	01/01/2019-12/31/19



		Share capital	Equity other than share capital	Share of holding	Value of the securities held before impairment losses	Value of the securities held after impairment losses	Loans and receivables granted by the Company and not Repaid	Sales total of the last fiscal year	Net profit or net loss of last fiscal year	Dividends received by Company in progress of the fiscal year	Notes
	Currencies in millions	Currencies in millions	In %	In millions of euros	In millions of euros	In millions of euros	Currencies in millions	Currencies in millions	In millions of euros		
bioMérieux Serbia	RSD	1.2	13.5	100.0%	0.0	0.0	0.0	0.0	3.4	0.0	01/01/2019-12/31/19
bioMérieux Singapore	SGD	0.1	4.0	100.0%	0.1	0.1	2.8	16.7	0.5	0.3	01/01/2019-12/31/19
AES Canada	CAD	0.0	(0.1)	100.0%	0.0	0.0	0.1	0.0	0.0	0.0	01/01/2019-12/31/19
BTF	AUD	4.1	22.5	100.0%	13.6	13.6	0.0	31.7	17.0	5.1	01/01/2019-12/31/19
Quercus Scientific NV	EUR	3.9	4.2	100.0%	19.9	19.9	0.0	0.0	0.0	0.2	01/01/2019-12/31/19
Total subsidiaries					747.2	651.3					
B - Investments (5%-50% owned by bioMérieux)											
Banyan Biomarkers Inc.	USD	6.1	0.0	19.3%	6.4	6.4	0.0	4.8	(4.8)	0.0	07/01/2017-06/30/18
GNEH	EUR	0.0	0.0	18.9%	4.2	3.2	0.0	0.0	0.0	0.0	Company created in 2018
Labtech system Ltd.	AUD	35.6	(6.0)	4.2%	1.3	1.0	0.0	2.9	(4.4)	0.0	07/01/2018-06/30/19
Lumed Inc.	CAD	0.8	(0.7)	16.3%	0.7	0.7	0.0	0.2	(0.4)	0.0	02/17-01/18 Unaudited
Mérieux Université	EUR	1.7	(0.6)	40.0%	1.6	0.4	0.0	5.1	(0.1)	0.0	01/01/2018-12/31/18
Qvella	CAD	54.8	(20.6)	5.7%	6.3	6.3	0.0	0.3	(4.0)	0.0	01/01/2017-12/31/17
Total equity investments					20.6	18.1					

	Share capital	Equity other than share capital	Share of holding	Value of the securities held before impairment losses	Value of the securities held after impairment losses	Loans and receivables granted by the Company and not Repaid	Sales total of the last fiscal year	Net profit or net loss of last fiscal year	Dividends received by Company in progress of the fiscal year	Notes	
	Currencies in millions	Currencies in millions	In %	In millions of euros	In millions of euros	In millions of euros	Currencies in millions	Currencies in millions	In millions of euros		
C - Other securities											
Amorçage Technologique Investissement	EUR	32.0	(12.3)	2.5%	0.8	0.8	0.0	0.0	(3.4)	0.0	01/01/2018-12/31/18
Avesthagen	INR	76.1	(1,217.3)	3.5%	1.4	0.0	0.0	0.0	(174.8)	0.0	04/01/2018-03/31/19
Dynavax	USD	1,131.3	(1,068.2)	0.0%	0.7	0.0	0.0	8.2	(158.9)	0.0	01/01/2017-12/31/17
Innovaprep	USD	0.0	0.0	3.5%	0.4	0.0	0.0	0.0	0.0	0.0	Company created in 2018
Knome Tafkak	USD	31.3	(31.3)	0.3%	7.3	0.0	0.0	0.0	(0.1)	0.0	01/18-12/18 Unaudited
LyonBiopôle	EUR	1.0	(1.1)	0.0%	0.3	0.0	0.0	1.1	0.0	0.0	01/01/2018-12/31/18
My Cartis	EUR	29.6	(27.2)	1.6%	1.2	0.0	0.0	0.6	(6.8)	0.0	01/01/2018-12/31/18
Sino French (Innovations) Fund II	EUR	0.0	0.0	1.4%	5.0	5.0	0.0	0.0	0.0	0.0	Company created in 2018
Supernova 2	EUR	9.6	(2.6)	1.3%	1.0	1.0	0.0	0.0	(1.7)	0.0	01/01/2018-12/31/18
Théra conseil	EUR	0.5	0.4	0.8%	0.0	0.0	0.0	5.8	0.1	0.0	01/01/2018-12/31/18
Total other securities					18.1	6.9					
GRAND TOTAL					785.9	676.3					

Note 4 Inventories

4.1 Accounting principles

Inventories are measured at the lower of cost and net realisable value.

Inventories of raw materials, consumables and goods for resale are measured at their purchase price plus related expenses using the FIFO method. Work-in-progress and finished products are measured at their actual production cost.

Inventories are written down where necessary, taking into account selling prices, obsolescence, residual shelf life, product condition, sale prospects and, in the case of spare parts, changes in the corresponding instruments' installed base.

4.2 Change

Inventories <i>In millions of euros</i>	12/31/2019	12/31/2018
Raw materials	41.9	39.9
Work-in-progress	28.1	26.9
Finished products and goods held for resale	90.1	104.8
TOTAL GROSS VALUE	160.1^(a)	171.6
Impairment losses	(10.6)	(10.1)
TOTAL CARRYING AMOUNT	149.5	161.5

(a) Including gross value of instruments and the related spare parts: 19.8% compared to 23.7% in 2018.

Note 5 Trade and operating receivables

5.1 Accounting principles

Receivables are recognised at face value. An impairment loss is recognised when the receivables present a risk of non-recovery.

5.2 Change

Trade receivables <i>In millions of euros</i>	12/31/2019	12/31/2018
Gross trade receivables	395.1	367.4
Impairment losses	(8.1)	(7.0)
CARRYING AMOUNT	387.0	360.4

Other operating receivables <i>In millions of euros</i>	12/31/2019	12/31/2018
Advances and downpayments	8.6	8.5
Prepaid expenses	5.6 ^(a)	4.5
Other operating receivables	20.1 ^(b)	19.8
TOTAL GROSS VALUE	34.3	32.8

(a) Prepaid expenses primarily consist of purchases of external charges.

(b) Including a VAT receivable for €14 million.

Maturities of trade and other receivables <i>Carrying amount in millions of euros</i>	12/31/2019	12/31/2018
Trade receivables	387.0	360.4
Due in less than one year	387.0	360.4
Due in more than one year		
Other operating receivables	34.3	32.8
Due in less than one year	34.2	32.6
Due in more than one year	0.1	0.2

Note 6 Cash at bank and in hand

6.1 Accounting principles

Cash and cash equivalents include available cash and short-term investments.

Changes in the cash pool are valued at the average monthly exchange rate. Cash pooling accounts are remeasured at the end

of the month at the closing rate. This remeasurement is offset by an entry to financial income and expenses taking into account currency hedges related to these positions.

6.2 Change

Cash at bank and in hand <i>In millions of euros</i>	12/31/2019	12/31/2018
Short-term investments	22.1	53.9
Cash pooling	44.8	43.6
Cash at bank and in hand, and financial instruments	152.0	128.3
TOTAL	219.1	225.8

Short-term investments break down as follows:

	12/31/2019	12/31/2018
Investment	Treasury shares	Treasury shares
Amount	€2.2 million	€31.3 million
Classification	Equities	Equities
ISIN Code	FR0010096479	FR0010096479
Investment	BNP PARIBAS DEPOSIT money-market fund	BNP PARIBAS DEPOSIT money-market fund
Net amount	€14.9 million	€17.6 million
Classification	Euro money-market fund	Euro money-market fund
ISIN Code	FR0011046085	FR0011046085
Investment	Time-deposit account	Time-deposit account
Amount	€5.0 million	€5.0 million
Classification	Euro money-market fund	Euro money-market fund
ISIN Code	-	-

Among short-term investments are 37,419 shares purchased within the framework of the establishment of a hedging program intended to ensure the cost of the various share grant plans.

Note 7 Translation adjustments

7.1 Accounting principles

In application of regulation ANC 2015-05, income and expenses in foreign currencies are recognised at their value in euros on the transaction date based on the average monthly exchange rate. Foreign exchange gains or losses on commercial transactions resulting from differences in rates between the transaction date and payment date are recognised under the corresponding line in the income statement (sales and purchases).

Receivables and payables in foreign currencies are converted based on their exchange rate on the closing date of the fiscal year. Any differences resulting from this valuation are recognised under unrealised foreign exchange gains and losses. Provisions are set aside for unrealised foreign exchange losses and are recognised in income (sales and purchases) whenever the receivable or payable is related to a commercial transaction.

When, for business transactions with relatively close maturities, unrealised foreign exchange gains and losses may be considered as contributing to an overall position, the amount of the allowance for exchange rate risks is capped at the excess of losses over gains. This estimate of losses takes into account, if applicable, the hedging rate linked to the derivative instruments related to these transactions.

Foreign exchange gains and losses concerning financial flows are recorded under financial income and expenses. Translations adjustments concerning cash pooling are recognised as income as well as hedging instruments symmetrically to the hedged item.

7.2 Unrealised foreign exchange losses

<i>In millions of euros</i>	12/31/2019	12/31/2018
On operating items	1.3	3.3
On borrowings and financial receivables	1.1	1.0
TOTAL	2.4	4.3

7.3 Unrealised foreign exchange gains

<i>In millions of euros</i>	12/31/2019	12/31/2018
On operating items	0.2	0.7
On borrowings and financial receivables	0.1	0.0
TOTAL	0.3	0.7

Note 8 Equity and share grant plans

8.1 Accounting principles

Investment grants are recognised in equity. The Company has elected to spread an investment grant financing an amortisable fixed asset over several periods. The investment grant is reversed over the same period based on the same pattern as the value of the asset acquired or created as a result of the grant.

Shares were acquired as part of a hedging plan, without specific allocation to a plan.

8.2 Change in shareholders' equity

The Company's share capital amounted to €12,029,370 at December 31, 2019 and was divided into 118,361,220 shares with a total of 197,362,371 voting rights (of which 79,001,151 shares carrying double voting rights). Following a decision taken by the General Meeting of March 19, 2001, the Company's bylaws no longer refer to a par value for its shares. No rights or securities with a dilutive impact on capital were outstanding at December 31, 2019.

At December 31, 2019, the Company held:

- 21,697 treasury shares under a liquidity agreement with an independent investment service provider. During 2019, the Company purchased 486,240 and sold 491,699 of its own shares;
- 37,419 treasury shares were purchased as part of a hedging programme for the various share grant plans. During the 2019 fiscal year, the Company did not purchase any shares, but awarded 422,700 and delivered 82,168 shares under the 2019 employee share ownership plan;
- in respect of the 2019 employee share ownership plan, 320,000 shares were vested and 82,168 were transferred from the free share grant plan. These shares were all delivered to employees at a preferential price.

<i>Change in shareholders' equity</i> <i>In millions of euros</i>	Share capital	Additional paid-in capital	Reserves & Retained Earnings	Statutory provisions	Subsidies	Total
EQUITY AT DECEMBER 31, 2018	12.0	63.5	919.0	59.9	0.1	1,054.6
Attributable net income for the period			119.6			119.6
Dividends paid			(41.3)			(41.3)
Changes in statutory provisions				0.4		0.4
EQUITY AT DECEMBER 31, 2019	12.0	63.5	997.3	60.3	0.1	1,133.2

The following table presents the Company's share grant plans:

Number of shares	Date on which plans opened				2019
	2015	2016	2017	2018	
Initial number of options granted	53,100	402,300	40,116	169,685	266,189
Options cancelled	6,600	25,200	1,431	4,275	27,759
Number of shares remitted in FY 2019	46,500	376,200			
Number of shares to be remitted as of Dec. 31, 2019		900	38,685	165,410	238,430

The number of shares for plans prior to 2017 were tripled after the three-for-one split decided by the Combined General Meeting of June 2017.

Between 2015 and 2019, the Board of Directors granted free shares (out of existing shares) to certain employees and corporate officers, subject to presence and performance conditions, as applicable.

Under the terms of the different plans, the free shares are subject to a vesting period of three or four years.

Furthermore, the vesting of performance shares is contingent on the achievement of objectives based on operating income, or on the achievement of specific objectives. The performance shares are no

longer subject to a lock-up period if the vesting period is at least two years. The lock-up period may be waived for shares granted to non-French tax residents provided that the shares concerned are subject to a four-year vesting period.

In 2019, after taking into account the rebilling of free shares, a net expense of €3 million was recognised in operating income/expenses (compared to a net expense of €8.8 million the previous year).

Given the 37,419 treasury shares held at December 31, 2019, the Company will have to purchase 406,006 additional shares at a cost of €32.2 million based on the share price at December 31, 2019.

8.3 Changes in statutory provisions

Statutory provisions <i>In millions of euros</i>	Accelerated amortisation	Provisions for price increases	Total
DECEMBER 31, 2018	58.0	1.9	59.9
Additions	11.7	0.5	12.2
Reversals	(11.5)	(0.2)	(11.7)
DECEMBER 31, 2019	58.2	2.2	60.4

Note 9 Provisions for contingencies and losses

9.1 Accounting principles

Contingency and loss provisions are recognised in accordance with French accounting rules applicable to liabilities (CRC 2000-06).

The Company is involved in a certain number of claims and litigation arising from the normal course of its business. It believes that these claims and litigation will not have a materially adverse impact on its ability to continue as a going concern. When a risk is identified, a provision is recognised as soon as it can be reliably estimated.

9.2 Change

Impairment <i>In millions of euros</i>	Other employee benefits ^(a)	Guarantees given ^(b)	Other provisions ^(c)	Total
DECEMBER 31, 2018	20.2	0.8	42.1	63.1
<i>Additions</i>	7.6	0.8	18.0	26.4
<i>Reversals (utilisations)</i>	(1.5)	(0.8)	(31.1)	(33.5)
<i>Reversals (surplus)</i>			(3.8)	(3.8)
Net additions (reversals)	6.1	0.0	(16.9)	(10.9)
DECEMBER 31, 2019	26.3	0.8	25.2	52.1

(a) Provisions for other employee benefits comprise retirement benefits, long-service awards and bonuses and mutual health insurance benefits. Reversals for the year were primarily due to the payment of €1 million made to the pension fund.

(b) Estimate of the costs relating to warranties issued on the sale of instruments in the period that may be incurred over the remaining warranty period.

(c) Including a provision for free share grants of €11.8 million, retirement benefit provisions for €3.8 million, provisions for commercial claims and litigation of €2.7 million, a provision for unrealised foreign exchange losses of €2.6 million, other provisions for charges of €2.6 million, and provisions covering losses on termination of sales contracts of €1.7 million.

9.3 Provisions for pensions and other post-employment benefits

9.3.1

The Company applies ANC recommendation No. 2013-02 of November 7, 2013 and applies the principles of IAS 19 as amended in June 2011 for its statutory financial statements, with the exception of the option to recognise actuarial gains and losses in equity.

9.3.2

Obligations in respect of pensions and other post-employment benefits are calculated using actuarial methods based on the following assumptions:

	Retirement benefits		Long-service awards	
	12/31/2019	12/31/2018	12/31/2019	12/31/2018
Salary increase rate	2.00%	2.00%	2.00%	2.00%
Discount rate	1.00%	2.00%	0.80%	1.60%
Employee mobility rate ^(a)	0% to 5%	0% to 5%	0% to 5%	0% to 5%
Average duration	14	13	10	9

(a) Depending on the age and status of the employee (managerial/non-managerial grade).

At December 31, 2019, the Company recognised provisions for retirement benefits of €11.5 million, compared to €6.8 million at December 31, 2018. In 2019, the Company paid €1 million to the

retirement benefits hedging fund. This hedging fund stood at €26.4 million at December 31, 2019.

The provision for long-service awards amounts to €14.8 million, compared to €13.3 million at December 31, 2018.

9.4 Contingent liabilities

The declared dispute with regard to the collective action of patients against bioMérieux as manufacturer of diagnostic tests for Lyme disease has not given rise to a provision for risk in the consolidated financial statements for the year ended December 31, 2019 as at this stage it is not possible to assess the risk incurred by the Company.

Note 10 Net debt

10.1 Statement of changes in net debt

The statement of changes in net debt includes all changes in borrowings and financial debt, regardless of maturity, net of cash and short-term bank borrowings.

It lists separately:

- cash flow relating to operating activities;
- cash flow relating to investing activities;
- cash flow relating to shareholders' equity.

Cash flow from operating activities corresponds to the aggregate of net income, depreciation and amortisation, net additions to provisions (impairment and contingencies and losses), less capital gains or losses on disposals of fixed assets.

Net debt corresponds to the Company's financial situation with regard to financing third parties outside of operating payables. This aggregate is determined by the sum of mandatory and bank debt (short, medium and long term) and bank overdrafts, less cash at bank and in hand and investment securities.

In millions of euros	12/31/2019	12/31/2018
Net income	119.6	75.1
Depreciation, amortisation and provisions, net	44.0	60.6
Gains and losses on Corporate actions	(30.4) ^(a)	(3.0)
Merger premium/loss		(1.2)
Cash flow from operating activities	133.3	131.6
Change in inventories	11.5	(13.7)
Increase of requirements in accounts receivable	(26.3) ^(b)	(41.3)
Change in trade payables and other operating working capital	1.5 ^(c)	17.6
Operating working capital requirement	(13.2)	(37.5)
Decrease in receivables, net of tax	11.0 ^(d)	19.5
Total change in working capital requirement	(2.2)	(18.0)
NET CASH FLOW FROM OPERATIONS	131.0	113.7
Investments	(66.2)	(69.0)
Income from disposal of fixed assets	52.3 ^(e)	8.6
Increase in net amounts payable on fixed assets	12.9 ^(f)	2.3
Equity acquisitions, subscriptions to capital increases	(82.2) ^(g)	(373.0) ^(h)
Net change in advances and loans to subsidiaries	43.5 ⁽ⁱ⁾	123.4 ⁽ⁱ⁾
Net change in other non-current financial assets	(0.8)	(7.1)
NET CASH FLOW FROM (USED IN) INVESTMENT ACTIVITIES	(40.7)	(314.7)
Dividends paid	(41.3)	(40.2)
Net cash used in shareholders' equity	(41.3)	(40.2)
Change in net debt (excluding exchange rate impact)	49.0	(241.3)
Breakdown of change in net debt		
Net debt at beginning of year	323.1	81.7
Net debt from the merger		(1.2)
Impact of changes in exchange rates on net debt		1.3
Change in net debt	(49.0)	241.3
• Committed debt	15.4	21.8
• Cash and bank overdrafts	(64.3)	219.4
NET DEBT AT END OF YEAR	274.1	323.1

(a) Including the capital gain on the disposal of Quanterix securities (-€30.5 million).

(b) Including amounts owed by Group customers (-€8.3 million) and by export customers (-€17.1 million).

(c) Including accrued payroll and other taxes (-€4.1 million), trade payables (+€4.8 million) and other receivables and operating payables (+€0.6 million).

(d) Including repayments obtained for the research tax credit (+€10.5 million).

(e) Including the disposal of Quanterix securities (€48.4 million).

(f) Including capital outstanding from bioMérieux Suzhou Biotech for €12.7 million.

(g) Including the capital increases of the subsidiaries bioMérieux China (-€64 million) and bioMérieux Argentina (-€3 million), the equity participation in the subsidiary bioMérieux Suzhou Biotech (-€20 million), and the capital reduction of bioMérieux HK (+€6 million).

(h) Including the capital increases of the subsidiaries ABG Stella (-€342 million), bioMérieux China (-€23.5 million), and bioMérieux Brazil (-€3 million), and the transfer value of the Geneuro shares to GNEH (-€4.2 million).

(i) Including the repayment of the bioMérieux Inc. loan (+€49.2 million), the bioMérieux GmbH loan (+1.6 million), the new South Africa loans (-€6.2 million), and the bioMérieux Egypt loans (-€1 million).

(j) Including repayment of the BioFire loan (+€72.3 million), the bioMérieux Inc. loan (+€49.2 million), the bioMérieux GmbH loan (+€3.2 million), and an additional loan to bioMérieux India (-€1.4 million).

10.2 Debt refinancing

bioMérieux SA has a syndicated credit facility for an amount of €500 million following the renegotiation of January 2017. The initial maturity of this loan is January 22, 2022 and may be extended twice for a duration of one additional year. Two extensions were exercised in 2018, deferring the maturity date to January 2024. This credit facility did not incur any drawdowns during 2019.

The syndicated credit facility is subject to the following covenant: bioMérieux Group net debt may not exceed 3.5 times operating income before non-recurring items (EBITDA) before depreciation/amortisation and acquisition expenses. The Company complied with this covenant at December 31, 2019.

bioMérieux SA had €50 million in outstanding commercial paper at December 31, 2019 (€35 million at December 31, 2018).

In early October 2013, bioMérieux SA carried out its first bond issue, placing €300 million worth of seven-year bonds (maturing October 14, 2020) with institutional investors. The bonds pay interest at an annual rate of 2.875%, and the sixth instalment was paid in October 2019 for €8.6 million. The bonds were issued with an issue premium. The

expense relating to the issue premium and bond issue fees is being amortised over the term of the bonds.

The financial cost of half of the bond issue has been transformed into a floating rate cost through the setting up of a swap contract that matures in July 2020, and has a 0.3% floor and is capped at 1.2 until July 2018. A swap contract in the opposite direction was set up in 2017 for the period between July 2018 and July 2020.

10.3 Debt schedule

<i>In millions of euros</i>	12/31/2019	12/31/2018
Due beyond 5 years	3.2	5.5
Due in 1 to 5 years	10.7	308.0
TOTAL DUE BEYOND 1 YEAR	13.9	313.5
Due within 1 year	479.3 ^(a)	235.4
TOTAL BORROWINGS	493.2	548.9
Short-term investments	(22.1) ^(b)	(53.9)
Cash at bank and in hand, and financial instruments	(197.0) ^(c)	(171.9)
NET DEBT	274.1	323.1

(a) Including a bond issue for €300 million, and cash pooling for €124.4 million, compared to €196.8 million at December 31, 2018.

(b) The book value of cash investments is identical to their market value, except for treasury shares, which are carried at historical cost.

(c) Including cash pooling for €44.8 million, compared to €43.6 million at December 31, 2018.

Note 11 Trade and operating payables

<i>Trade and other operating payables</i> <i>In millions of euros</i>	12/31/2019	12/31/2018
Trade payables	168.7	163.9
Accrued payroll and other taxes	126.2	130.3
Deferred income	4.7 ^(a)	3.4
Other payables	11.8	10.8
Other operating payables	142.6	144.4

(a) Including a lease and maintenance agreement for €3.5 million and the sale of reagents and instruments for €1.2 million.

<i>Trade and other operating payables</i> <i>In millions of euros</i>	12/31/2019	12/31/2018
Trade payables		
Due within one year	168.7	163.9
TOTAL	168.7	163.9
Other operating payables		
Due within one year	142.4	144.4
Due beyond one year	0.2	
TOTAL	142.6	144.4

Note 12 Accrued expenses and income

Accrued expenses and income <i>In millions of euros</i>	12/31/2019	12/31/2018
Miscellaneous borrowings	2.3	2.5
Trade payables	50.1	52.4
Accrued payroll and other taxes	112.2	115.1
Other operating payables	10.0	8.6
Other non-operating payables	12.7 ^(a)	14.9
TOTAL ACCRUED EXPENSES	187.3	193.5
TOTAL ACCRUED INCOME	21.2^(b)	27.5

(a) Including €3.6 million of the Sino-French Innovation Fund 2 securities balance, compared to €4.7 million at December 31, 2018.

(b) Including unbilled customer payables (€17.9 million compared to €24.2 million at December 31, 2018) and accrued interest on loans to subsidiaries (€2 million at December 31, 2019 and December 31, 2018).

Note 13 Sales

13.1 Accounting principles

Revenue from product sales (reagents and instruments) and related services (after-sales, training, delivery, etc.) are presented in "revenues" in the profit & loss statement.

Revenue arising from the sale of products is recognised when all of the following criteria have been satisfied:

- the significant risks and rewards of ownership have been transferred to the buyer;
- the Company no longer has a continuing involvement in the effective control over the goods sold;
- the revenue and the costs incurred or to be incurred in relation to the transaction can be measured reliably;
- it is probable that the economic benefits associated with the transaction will flow to the Company.

These criteria are satisfied when reagents are delivered and when sold instruments are installed.

In the case of services (training, technical support, etc.), revenue is recognised only after the services have been rendered. Revenue from instrument maintenance contracts is deferred and recognised on the basis of the elapsed portion of the service contract.

Sales are measured at the fair value of the consideration received or receivable, net of any discounts and rebates granted to customers. Sales taxes and value-added taxes are not included in sales.

13.2 Change

Breakdown of sales <i>In millions of euros</i>	France	Export	Total 12/31/2019	Total 12/31/2018
Sales of goods for resale	12.9	122.8	135.7	128.4
Sold production (goods)	159.9	729.6	889.5	860.1
Sold production (services)	21.1	211.9	233.0	200.3
TOTAL	193.8	1,064.4	1,258.2	1,188.8

Revenues by geographic area <i>In millions of euros</i>	12/31/2019	12/31/2018
France & Dom Tom	197.7	200.8
Europe, Africa, Middle East	512.2	479.5
South America	44.5	40.4
North America	145.7	154.9
Asia Pacific	173.6	159.8
Other related activities not broken down	184.5	153.4
TOTAL	1,258.2	1,188.8

Note 14 Research & development expenses

Research & development expenses are expensed as incurred except for research & development programs capitalised following the merger with the companies AES Chemunex and CEERAM.

Research & development expenses at December 31, 2019 amounted to €123.1 million, compared to €121 million the previous year.

Note 15 Personnel costs and employee benefits

15.1 Accounting principles

When an expense is not considered as definitive on recognition, the expense transfer accounts are used to subsequently reclassify the expense based on the appropriate economic nature.

15.2 Change

Personnel costs <i>In millions of euros</i>	12/31/2019 12 months	12/31/2018 12 months
Wages and salaries	197.8	192.9
Discretionary profit-sharing	16.5	17.2
Payroll taxes	95.3	103.4
TOTAL	309.7	313.5
AVERAGE HEADCOUNT	3,674	3,649
HEADCOUNT AT YEAR-END	3,686	3,679

In accordance with the law, no non-discretionary profit-shares could be granted to employees out of net income for 2019.

Compensation allocated to members of the administrative, management and supervisory bodies and senior management

(Company directors and members of the Executive Committee who are employees of the Company) in respect of their duties in 2019 consisted of directors' fees of €0.4 million, and fixed and variable compensation of €7.1 million.

Breakdown of headcount <i>In FTE</i>	12/31/2019 12 months	12/31/2018 12 months
AVERAGE HEADCOUNT		
Managers	1,794	1,790
Supervisors	53	63
Employees	30	27
Technicians	1,190	1,181
Blue-collar workers	607	588
TOTAL	3,674	3,649
HEADCOUNT AT YEAR-END		
Managers	1,818	1,813
Supervisors	53	66
Employees	38	29
Technicians	1,176	1,177
Blue-collar workers	601	594
TOTAL	3,686	3,679

Note 16 Net financial expenses

16.1 Accounting principles

Dividends received are recognised net of withholding taxes applicable in the country of origin.

16.2 Change

<i>In millions of euros</i>	12/31/2019	12/31/2018
Net finance costs	(5.3)	(3.5)
Impairment of investments	(3.9) ^(a)	(9.5) ^(b)
Merger premium/loss		1.2
Provisions for financial contingencies and losses		0.2
Dividends	42.4	25.3
Foreign exchange gains (losses)	3.5	(1.0)
TOTAL	36.8	12.6

(a) Including net additions relating to shares in subsidiaries for €4 million, and -€0.1 million relating to other investments.

(b) Including net additions relating to shares in subsidiaries for €7.7 million, and €1.8 million relating to other investments.

bioMérieux SA absorbed SAS International on July 30, 2018 with retroactive tax effect to January 1, 2018. The contributions measured at their net book value resulted in a merger premium of €1.2 million during the previous fiscal year.

16.3 Foreign exchange gains (losses)

Foreign exchange gains and losses result from differences between the transaction exchange rate and the settlement rate (or the year-end rate if the payment has not yet been made). These differences only partially reflect the impact of currency fluctuations.

Foreign exchange gains and losses on commercial transactions are recognised under the relevant headings in the consolidated income statement. The table below shows their income statement impact:

<i>In millions of euros</i>	12/31/2019	12/31/2018
Operation	(10.7)	(7.3)
Financial items	3.5	(1.0)
TOTAL	(7.3)	(8.3)

Note 17 Non-recurring income

<i>In millions of euros</i>	Income	Expenses	Net 12/31/2019	Net 12/31/2018
Exits and disposals of fixed assets	52.3	21.9	30.3	2.9
Statutory provisions	11.7	12.1	(0.4)	(1.0)
Other non-recurring income and expenses	21.4	24.9	(3.6)	1.8
TOTAL	85.3	59.0	26.4	3.7

Disposals of fixed assets take into account the €30.5 million in capital gains from the disposal of Quanterix securities.

Note 18 Corporate income tax

18.1 Change

At December 31, 2019, the Company recognised various tax credits totalling €22 million, including a research tax credit for an estimated €19 million. These various tax credits accumulated since 2018 represented the majority of non-operating receivables at December 31, 2019, and have a maturity of less than one year.

The net Corporate income tax expense totalled €1.1 million in 2019, compared to income of €0.6 million the previous year.

18.1.1

<i>In millions of euros</i>	Before tax	Tax	12/31/2019 After tax	12/31/2018
Recurring income	94.3	(1.4)	92.9	70.9
Non-recurring income	26.4	0.1	26.5	3.7
Prior-year adjust.		0.2	0.2	0.5
NET INCOME FOR THE YEAR	120.7	(1.1)	119.6	75.1

18.1.2

<i>In millions of euros</i>	12/31/2019	12/31/2018
Net income for the year	119.6	75.1
Income tax	(1.1)	0.6
Net income before tax	120.6	74.5
Accelerated depreciation, amortisation and statutory provisions	(0.4)	(1.0)
Total valuation allowances	(0.4)	(1.0)
NET INCOME BEFORE TAX AND EXCLUDING VALUATION ALLOWANCES	121.0	75.5
Income tax	(1.1)	0.6
Tax on valuation allowances (34.43%)	0.1	0.3
NET TAX BENEFIT (EXPENSE)	(1.2)	0.3
NET INCOME FOR THE FISCAL YEAR EXCLUDING VALUATION ALLOWANCES	119.9	75.8

18.1.3

<i>In millions of euros</i>	12/31/2019 Rate 32.02%	12/31/2018 Rate 34.43%
Accelerated depreciation, amortisation and statutory provisions	19.3	20.6
TOTAL DEFERRED TAX LIABILITIES	19.3	20.7
Non-deductible provisions and expenses	(10.5)	(6.9)
Unrealised foreign exchange gains	(0.1)	(0.2)
TOTAL DEFERRED TAX ASSETS	(10.5)	(7.2)
TOTAL DEFERRED TAX BENEFIT OR EXPENSE	8.8	13.5

Note 19 Hedging instruments

19.1 Accounting principles

The Company only uses financial instruments for hedging purposes, in order to limit risks stemming from changes in exchange rates and interest rates, whether related to assets and liabilities at the end of the period or to future transactions.

19.2 Exchange rate risk

In view of the significant proportion of bioMérieux SA's operations conducted outside the euro zone, its sales, earnings and assets and liabilities may be impacted by changes in exchange rates between the euro and other currencies. Sales are particularly affected by euro/US dollar exchange rate variations and, more occasionally, by fluctuations in the rate of the euro against other currencies.

bioMérieux SA's current policy is to seek to hedge the impact of exchange rate fluctuations on budgeted net income. It uses hedging instruments, when they are available at a reasonable cost, in order to mitigate risks relating to currency fluctuations. Hedging contracts are purchased to cover transactions included in the budget and not for speculative purposes.

Hedges consist mainly of forward currency sales and purchases (maturing within 18 months at December 31, 2019).

Hedging instruments used are backed against trade and financial receivables and payables.

Unrealised foreign exchange gains and losses on hedging instruments, related to the basis of trading prices at December 31, 2019 are

recognised in the balance sheet whenever they are in a hedging relationship with receivables or payables.

Hedges in effect at December 31, 2019 were as follows:

- forward sales of €23.4 million to hedge trade receivables;
- forward sales of €24.0 million to hedge financial receivables;
- forward purchases of €80.0 million to hedge borrowings.

Furthermore, currency hedges were set up to cover the budget positions of the 2019 fiscal year. The net amount of these hedges is €198.1 million.

The market value at December 31, 2019 of all the budget hedges represents an unrealised loss of €0.3 million.

At December 31, 2019, the Company had no hedges covering the earnings of foreign subsidiaries.

The market value at December 31, 2019 of financial hedges represents an unrealised loss of €0.6 million.

The table below shows the currencies in which revenues were generated:

In millions of euros	12/31/2019		12/31/2018	
	12 months	%	12 months	%
Euro	727.8	58%	673.8	57%
Other				
US dollar	187.0	15%	193.0	16%
Chinese Yuan	67.0	5%	69.4	6%
Indian rupee	36.0	3%	30.2	3%
Pound sterling	34.8	3%	32.7	3%
Czech koruna	33.2	3%	31.7	3%
Swiss franc	22.0	2%	20.8	2%
Swedish krona	18.1	1%	18.5	2%
Turkish lira	13.0	1%	10.5	1%
South African rand	12.3	1%	15.8	1%
Brazilian real	7.6	1%	6.9	1%
Other currencies	99.3	8%	85.4	7%
TOTAL	1,258.2	100%	1,188.8	100%

19.3 Rate risk

19.3.1

As part of its interest rate risk management policy aimed at managing the risk of an increase in interest rates, bioMérieux SA hedges part of its debt.

The bond issue, after accounting for interest rate derivatives, is at a fixed rate until maturity in 2020. The expense in respect of the related premiums is being amortised over the term of the hedges.

The real estate lease financing agreement in the amount of €45 million set up in 2015 to finance Campus de l'Etoile is variable-rate and indexed. At December 31, 2019, there was no mechanism set up to back this financing.

Exposure to interest rate risk on other borrowings is not material and is not subject to hedging.

19.3.2

At December 31, 2019, the interest rate risk hedging portfolio comprised interest rate swaps with no sensitivity to rate risk since €150 million in fixed rate payer swaps established in April 2017 cancelled the impact of the variable rate payer swaps of €150 million until their maturity in 2020.

The market value of these rate swaps amounted to a €2.2 million.

19.4 Exchange rate and interest rate risk

In 2013, bioMérieux SA issued bonds in euros in connection with its US dollar-denominated acquisition of US-based BioFire by bioMérieux Inc., which closed in January 2014. In January 2014, bioMérieux SA granted a loan of US\$470 million to bioMérieux Inc. These transactions generated a combined exchange rate risk and interest rate risk that needed to be hedged.

19.4.2

In order to mitigate the above-described exchange rate and interest rate risk, the Company set up a cross currency swap in January 2014.

Cross currency swaps in the amount of US\$470 million have been exchanged. This nominal amount is payable in six-monthly instalments.

At December 2019, the outstanding nominal amount of cross currency swaps stood at US\$67.1 million. The market value of these instruments amounted to a negative €10.9 million.

Note 20 Off-balance sheet commitments

20.1 Financial commitments

20.1.1

<i>In millions of euros</i>	12/31/2019	12/31/2018
Endorsements and guarantees	124.0 ^(a)	200.6
Finance lease and rent commitments	38.3	37.8
TOTAL	162.3	238.4

(a) Of which related parties for €122.4 million.

In 2018, bioMérieux SA stood surety for the RMB655 million (€83 million) loan taken by bioMérieux Shanghai as part of the financing of the acquisition in 2018 of the majority of the shares making up the share capital of Suzhou Hybiome Biomedical Engineering Co. Ltd.

<i>Finance lease</i> <i>In millions of euros</i>	Gross	Royalties		Amotisation and depreciation	
		fiscal year	cumulative	fiscal year	cumulative
Land	2.3	0.2	0.6		
Buildings	42.1	3.7	12.1	2.5	8.0
TOTAL	44.4	3.9	12.6	2.5	8.0

<i>Finance lease</i> <i>In millions of euros</i>	Outstanding royalties				Residual value
	< 1 year	1-5 years	> 5 years	Total	
Land	0.2	0.8	0.7	1.7	
Buildings	3.7	14.6	13.7	31.9	
TOTAL	3.9	15.4	14.4	33.7	

20.1.2

<i>In millions of euros</i>	12/31/2019	12/31/2018
Credit facilities with a banking syndicate	500.0	500.0
TOTAL	500.0	500.0

20.2 Research & development commitments

At December 31, 2019, commitments given in respect of various research agreements amounted to €3 million.

bioMérieux SA participates in a research program coordinated by Institut Mérieux, together with bioMérieux, Transgène, Genosafe and the Genethon association. The aim of this program is to develop a new generation of diagnoses and therapies focusing on cancers, infectious diseases and genetic disorders. This program is known under the acronym "ADNA" (for "Advanced Diagnostics for New therapeutic Approaches"). The program receives financing from the French government's Industrial Innovation Agency (*Agence de l'Innovation Industrielle*), which merged with OSEO ANVAR in 2007, and was renamed Bpifrance in July 2013. The public financing agreement was approved by the European authorities on October 22, 2008. In this

context, and in light of the supplemental agreements modifying the initial research program, bioMérieux SA had agreed to undertake research & development for an estimated amount of €67.5 million and updated to €54.5 million. The liquidating assessment was carried out in 2017. At December 31, 2019, the Company had no more undertakings to carry out research & development work. In return, bioMérieux SA received subsidies (€16.1 million) and repayable grants (€7.5 million). If the products resulting from this research are commercially successful, bioMérieux SA will have to pay back these grants according to a payment schedule based on the revenue generated from these products, and will also have to pay a share of profits until 2029 (3.4% of revenue earned on the relevant products).

bioMérieux SA entered into a ten-year partnership with BIOASTER, a Technological Research Institute in Lyon specialised in infectious diseases. In the period 2012-2015, its contribution to research activities resulted in new partnership agreements being put in place with BIOASTER for almost €4 million. bioMérieux's own employees are also involved in these partnership agreements. A new collaboration cycle was opened for the period between January 1, 2016 and end of July 2020 during which bioMérieux SA has made a commitment to BIOASTER in the same proportions.

20.3 Commitments relating to equity investments

bioMérieux SA has committed with Amorçage Technologique Investissement (ATI) to responding to new calls for funds up to an amount of €0.2 million.

bioMérieux SA has committed to paying the unpaid capital of bioMérieux Suzhou Biotech Co.Ltd. in January 2020 for 11.5 million Chinese yuan.

Note 21 Related parties

21.1 Affiliated companies: balance sheet items

<i>In millions of euros</i>	12/31/2019	12/31/2018
TOTAL NON-CURRENT FINANCIAL ASSETS	847.9	826.3
TOTAL RECEIVABLES	254.5	253.4
Total cash at bank and in hand^(a)	44.8	43.6
Operating payables	81.7	84.4
Borrowings ^(b)	124.4	196.8
TOTAL PAYABLES	206.1	281.2

(a) Advances to subsidiaries for cash pooling.

(b) Advances from subsidiaries for cash pooling.

21.2 Affiliated companies: financial income and expenses

<i>In millions of euros</i>	12/31/2019 12 months	12/31/2018 12 months
Net impairment of investments	(4.0)	(8.7)
Financial expenses	(15.0)	(27.7)
Dividends received	42.4	25.3
Financial income	20.0	43.6
TOTAL	43.4	32.5

Financial income includes exchange gains following the revaluation of the cash pooling (€9.6 million), as well as interest on loans to subsidiaries and cash pooling (€6.6 million) of which €4.5 million for interest on the bioMérieux Inc. loan, €0.6 million for interest on the RAS loan, €0.4 million for interest on the South Africa loan, and

€1.1 million for interest on cash pooling. Financial income also includes the net gains on transactions on equity investments for €2.2 million.

Financial expenses recorded foreign exchanges losses on cash pooling (€11.8 million), unrealised exchange losses on long-term loans (€0.2 million for the loan granted to RAS), as well as interest on cash pooling (€2.7 million).



21.3 Related party transactions

The Institut Mérieux, which held 58.9% of bioMérieux SA at December 31, 2019, performed research and services at bioMérieux SA for a total of €8.3 million for the year, from which €2.9 million were rebilled to bioMérieux Inc. and €2 million to BioFire. bioMérieux SA rebilled €0.9 million to Institut Mérieux for expenses paid on its behalf.

The Company rebilled €4.3 million worth of services and reagent sales to entities of the Mérieux NutriSciences Corporation Group, in which Institut Mérieux holds a majority interest. Unlike Group companies, Mérieux NutriSciences Corporation rebilled bioMérieux SA for €0.2 million in services.

Théra Conseil, which is 99.2%-owned by Institut Mérieux, billed bioMérieux SA €1.7 million for services in respect of 2019.

bioMérieux SA contributed €2 million to the Fondation Christophe and Rodolphe Mérieux for humanitarian projects.

bioMérieux SA paid the Fondation Mérieux €0.1 million for expenses incurred on its behalf.

bioMérieux SA paid €3.9 million to Mérieux Université (in which bioMérieux SA and Institut Mérieux each hold a 40% interest, and Mérieux NutriSciences Corporation holds a 20% interest) in respect of training fees, and rebilled €1.8 million in other services.

ABL Inc., indirectly wholly owned by Institut Mérieux, billed bioMérieux SA for raw materials supplies for €1 million and fees for €0.2 million. bioMérieux SA rebilled other ABL Group companies for instruments and reagents for €0.1 million. Conversely, €0.1 million was rebilled for research expenses.

The companies of the Pierre Fabre Group were billed €0.5 million for services and reagent sales.

BIOASTER billed bioMérieux SA €0.5 million for research expenses and fees. bioMérieux SA, in turn, rebilled BIOASTER €0.1 million for services.

bioMérieux SA made a €0.1 million donation to the Université de Lyon Foundation.

Lastly, Lumed billed research expenses for €0.6 million.

6.2.3 Analysis of the results and other financial information

6.2.3.1 Revenue and financial position

During the year ended December 31, 2019, the Company's sales amounted to €1,258 million compared to €1,189 million for the previous year, representing a year-on-year increase of 5.8%.

The growth in revenues was mainly attributable to the 11.2% increase in export sales (mainly to distributors), the 3.5% rise in sales to subsidiaries in a context of global Group growth, as well as to the 17% increase in other income. On the other hand, domestic sales decreased by 1.6% due to the decrease in sales volumes for the immunoassays ranges despite the growth in the molecular biology lines.

Gross operating income came in at €164 million, *i.e.* 13% of sales. It increased by €10.1 million, up 6.6%, compared to the previous fiscal year, mainly due to the growth in business (6%) partially offset by the change in external expenses (16.9%).

After depreciation, amortisation and provisions, operating income decreased by €0.7 million, dropping from €58.2 million in 2018 to €57.5 million at December 31, 2019.

The 23.3% increase in amortisation and provisions results mainly from provisions for the free share grants and retirement benefits, offset by the growth in gross operating income.

In 2019, net financial income came in at €36.8 million *versus* €12.6 million the previous year.

This change is primarily due to the €17.1 million increase in dividends received and the €5.6 million decrease in provisions for equity investments.

Net income before non-recurring items and tax totalled €94.2 million *versus* €70.8 million one year earlier.

Non-recurring income at December 31, 2019 was income of €26.4 million compared to €3.7 million at December 31, 2018, mainly due to income from the disposal of financial securities in 2019.

Income tax amounted to a net expense of €1.1 million, compared to income of €0.6 million at December 31, 2018.

The €23 million income tax expense (*versus* €20.1 million in 2018) was almost completely offset by tax credits, primarily the provisioned research tax credit of €19 million, compared to €17.9 million in 2018.

Net income for the fiscal year amounts to €119.6 million compared with €75.1 million the previous year, *i.e.* a year-on-year increase of €44.5 million. It represents 9.5% of sales, compared to 6.3% at December 31, 2018.

Investments in intangible assets represent €6.7 million and primarily concern developments of IT solutions.

Capital expenditure, amounting to €59.3 million, mainly concerned the equipment of the Craponne (R&D) and Marcy (manufacturing) sites.

Non-current financial assets (acquisitions/disposals) increased by €21.6 million in gross value, primarily because of the subscriptions and capital increases (including bioMérieux HK China for €64.2 million, and bioMérieux Suzhou Biotech Co. Ltd. for €20 million), partially offset by the €49.2 million repayment on the loan granted to bioMérieux Inc. and the disposal of Quanterix investment securities for €17.9 million.

6.2.3.2

Shareholders will be invited to appropriate distributable net income for the year ended December 31, 2019, totalling €200,129,054.79, consisting of €119,592,998.59 in net income and €80,536,056.20 in retained earnings, as follows:

- €60,000,000 to be transferred to the "General Reserve" account, increasing the balance from €795,000,000.28 to €855,000,000.28;
- €57,473.61 to be transferred to the "Special sponsorship reserve", increasing the balance from €935,618.97 to €993,092.58;
- €44,977,263.60 distributed in dividends, representing a dividend of €0.38 for each of the 118,361,220 shares comprising the share capital; to be paid on June 4, 2020;

- the balance of €95,094,317.58 will be paid to "Retained Earnings".

In accordance with the provisions of article L.225-210 of the French Commercial Code (*Code de commerce*), the Company will not receive any dividends on treasury shares held on the ex-dividend date. The corresponding dividend amount will be allocated to "Retained earnings".

Under current French tax legislation, the dividends distributed to individuals domiciled in France for tax purposes are taxed in two phases:

- at their payment, the gross amount is subject to a non-discharging levy (French acronym PNFL) of 12.8% for income tax (Article 117 *quater* of the French Tax Code (*Code général des impôts*)) and social security withholdings of 17.2%. Low-income taxpayers may request exemption from the PNFL;
- the following year, they are subject:
 - to tax at the flat rate of 12.8% (single flat-rate levy),
 - or, on option, to the progressive income tax scale. In this case, a 40% allowance (Article 158, 3^e of the French Tax Code (*Code général des impôts*)) is applicable.

The PNFL of 12.8% deducted during the payment year is deducted in this case from income tax. The excess is refunded, if applicable.

The dividends paid for each of the past three years are presented in section 7.6.

The 2019 financial statements include non-tax-deductible expenses as provided for in articles 223 *quater* and 223 *quinquies* of the French Tax Code (*Code général des impôts*) amounting to €502,224. These correspond to the non-deductible portion of rental payments and depreciation charges for vehicles leased and purchased by bioMérieux SA. Income tax at the base rate paid in this respect amounted to €167,408.

6.2.3.3 Five-year financial summary (article R.225-102 of the French Commercial Code (*Code de commerce*))

	Fiscal year 12/31/2019	Fiscal year 12/31/2018	Fiscal year 12/31/2017	Fiscal year 12/31/2016	Fiscal year 12/31/2015
I. Share capital at year-end					
Share capital (<i>in euros</i>)	12,029,370	12,029,370	12,029,370	12,029,370	12,029,370
Number of ordinary shares outstanding ^(a)	118,361,220	118,361,220	118,361,220	39,453,740	39,453,740
Number of preferred shares (without voting rights) outstanding	0	0	0	0	0
Maximum number of potential shares to be issued	0	0	0	0	0
By conversion of bonds	0	0	0	0	0
By exercise of subscription rights	0	0	0	0	0
II. Transactions and net income for the fiscal year (<i>in euros</i>)					
Sales	1,258,157,229	1,188,752,991	1,137,563,972	1,038,853,374	961,955,147
Income before tax, employee profit-sharing, depreciation, amortisation and provisions	164,775,272	135,210,344	167,690,845	81,341,294	150,431,236
Income tax ^(b)	1,139,111	(562,410)	(2,294,743)	(8,533,578)	(1,081,437)
Employee profit-sharing for the year				0	0
Income after tax, employee profit-sharing, depreciation, amortisation and provisions	119,592,999	75,140,870	109,199,429	69,111,739	75,654,871
Dividends paid ^(c)	44,977,264	41,426,427	40,242,815	39,453,740	39,453,740
Special dividend paid from the general reserve	0	0	0	0	0
III. Earnings per share (<i>in euros per share</i>)					
Income after tax and employee profit-sharing, but before depreciation, amortisation and provisions	1.38	1.15	1.44	2.28	3.83
Income after tax, employee profit-sharing, depreciation, amortisation and provisions	1.01	0.63	0.92	1.75	1.92
Dividend per share	0.38	0.35	0.34	1.00	1.00
IV. Employee data					
Average number of employees during the year ^(d)	3,674	3,649	3,554	3,427	3,326
Total annual payroll (<i>in euros</i>)	215,921,602	211,591,174	199,088,838	187,804,208	177,082,713
Total employee benefits paid during the year (social security, charities) (<i>in euros</i>)	93,736,765	101,882,387	88,884,116	84,651,059	80,796,671

(a) The number of shares was tripled in 2017 after the three-for-one split decided by the Ordinary and/or Extraordinary Shareholders' Meetings of June 2017.

(b) The negative amounts correspond to tax income.

(c) Subject to the non-payment of dividends on treasury shares held on the ex-dividend date.

(d) Excluding interns and international work experience volunteers (VIE), data changed from that previously published in order to homogenise the headcount.

6.2.3.4 Information on payment periods

In accordance with article D.441.4 of the French Commercial Code (*Code de commerce*), invoices received and not paid at December 31, 2019 that are in arrears are broken down as follows:

SUPPLIER INVOICES (NON-GROUP)

Invoices received that have not been settled on the balance sheet date and are in arrears

	0 day (Indicative)	1 to 30 days	31 to 60 days	61 to 90 days	More than 91 days	Total (More than 1 days)
(A) Late payment ranges						
Number of invoices concerned	201	105	137	81	389	712
Total amount of invoices concerned (inclusive of tax)	1,304,039	645,733	930,932	533,395	1,278,065	3,388,124
Percentage of the total amount of purchases for the year	0.27%	0.13%	0.19%	0.11%	0.26%	0.69%

(B) Invoices excluded from (A) relating to disputed debts or unrecognised debts

Number of invoices excluded

Total amount of invoices excluded (inclusive of tax)

(C) Reference payment period used (contractual or legal period - article L.441-6 or article L.443-1 of the French Commercial Code (*Code de commerce*))

Payment schedules used in calculating late payments Contractual period: 0 to 45 days from the end of the month, according to the contract

SUPPLIER INVOICES (NON-GROUP AND GROUP)

Invoices received that have not been settled on the balance sheet date and are in arrears

	0 day (Indicative)	1 to 30 days	31 to 60 days	61 to 90 days	More than 91 days	Total (More than 1 days)
(A) Late payment ranges						
Number of invoices concerned	201	115	156	84	419	774
Total amount of invoices concerned (inclusive of tax)	1,304,039	1,306,669	2,116,764	1,261,514	3,788,510	8,473,457
Percentage of the total amount of purchases for the year	0.15%	0.16%	0.26%	0.16%	0.48%	1.05%

(B) Invoices excluded from (A) relating to disputed debts or unrecognised debts

Number of invoices excluded

Total amount of invoices excluded (inclusive of tax)

(C) Reference payment period used (contractual or legal period - article L.441-6 or article L.443-1 of the French Commercial Code (*Code de commerce*))

Payment schedules used in calculating late payments Contractual period: 0 to 60 days from the end of the month, according to the contract for suppliers

In accordance with article D.441.4 of the French Commercial Code (*Code de commerce*), invoices issued and not paid at December 31, 2019 that are in arrears are broken down as follows:

CLIENT INVOICES (NON-GROUP)

Invoices issued that have not been settled on the balance sheet date and are in arrears

	0 day (Indicative)	1 to 30 days	31 to 60 days	61 to 90 days	More than 91 days	Total (more than 1 days)
(A) Late payment ranges						
Number of invoices concerned	3,417	2,175	1,947	886	3,791	8,799
Total amount of invoices concerned (inclusive of tax)	9,169,822	6,090,369	6,233,389	3,018,961	5,876,747	21,219,466
Percentage of revenue for the fiscal year	2.44%	1.62%	1.66%	0.80%	1.56%	5.64%
(B) Invoices excluded from (A) relating to disputed or unrecognised receivables						
Number of invoices excluded				1,140		
Total amount of invoices excluded (inclusive of tax)				12,551,506		
(C) Reference payment periods used						
Payment schedules used in calculating late payments	Contractual periods:		France: between 30 days from the end of the month and 60 clear days Export: between 30 clear days and 120 clear days			

CLIENT INVOICES (NON-GROUP AND GROUP)

Invoices issued that have not been settled on the balance sheet date and are in arrears

	0 day (Indicative)	1 to 30 days	31 to 60 days	61 to 90 days	More than 91 days	Total (more than 1 days)
(A) Late payment ranges						
Number of invoices concerned	3,421	2,518	2,014	916	3,974	9,422
Total amount of invoices concerned (inclusive of tax)	9,008,565	13,574,072	7,445,012	3,279,093	9,005,796	33,303,973
Percentage of revenue for the fiscal year	0.72%	1.08%	0.59%	0.26%	0.72%	2.65%
(B) Invoices excluded from (A) relating to disputed or unrecognised receivables						
Number of invoices excluded				1,140		
Total amount of invoices excluded (inclusive of tax)				12,551,506		
(C) Reference payment period used (contractual or legal period - article L.441-6 or article L.443-1 of the French Commercial Code (<i>Code de commerce</i>))						
Payment schedules used in calculating late payments	Contractual periods:		France: between 30 days from the end of the month and 60 clear days Export: between 30 clear days and 120 clear days			